FDA Removes 12 Peptides from 503A Category 2 : r us_pharmacies FDA Peptide Reclassification 2026: What It Means for Providers : ? The FDA just removed 12 peptides (BPC157, TB500, Epitalon, GHKCu inj., DSIP, MOTSc, Semax, PEGMGF, Melanotan II, LL37, Dihexa, KPV) from Category 2 (donotcompound Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy The reason peptide access is changing comes down to two regulatory categories most patients don't know exist: 503A and 503B. 503A = traditional compounding pharmacies. State licensed, patient specific prescriptions. 503B = FDA registered outsourcing